Клинический разбор в общей медицине

1. Hodis HN, Mack WJ. Menopausal Hormone Replacement Therapy and Reduction of All-Cause Mortality and Cardiovascular Disease: It Is About Time and Timing. Cancer J 2022;28(3):208-23. DOI: 10.1097/PPO.0000000000000591

2. Panay N, Palacios S, Davison S, Baber R. Women’s perception of the menopause transition: a multinational, prospective, community-based survey. GREM Gynecological and Reproductive Endocrinology & Metabolism 2021;(03):178-83 DOI: 10.53260/GREM.212037

3. Сабгайда Т.П., Ростовская Т.К. Смертность женщин в Российской Федерации. Экология человека. 2020;(11):46-52.

Sabgaida T.P., Rostovskaya T.K. Mortality of women in the Russian Federation. Human Ecology. 2020;(11):46-52 (in Russian).

4. Шляхто Е.В., Сухих Г.Т., Серов В.Н. и др. Российские критерии приемлемости назначения менопаузальной гормональной терапии пациенткам с сердечно-сосудистыми и метаболическими заболеваниями. Согласительный документ Российского Кардиологического Общества, Российского Общества Акушеров-Гинекологов, Российской Ассоциации Эндокринологов, Евразийской Ассоциации, Терапевтов, Ассоциации Флебологов России. Кардиология. 2023;63(10):9-20.

Shlyakhto E.V., Sukhoi G.T., Serov V.N. et al. Russian criteria for the acceptability of prescribing menopausal hormone therapy to patients with cardiovascular and metabolic diseases. The agreement document of the Russian Cardiological Society, the Russian Society of Obstetricians and Gynecologists, the Russian Association of Endocrinologists, the Eurasian Association of Therapists, the Association of Phlebologists of Russia. Cardiology. 2023;63(10):9-20 (in Russian).

5. El Khoudary SR, Greendale G, Crawford SL et al. The menopause transition and women’s health at midlife: a progress report from the Study of Women’s Health Across the Nation (SWAN). Menopause 2019;26(10):1213-27.

6. Huan L, Deng X, He M et al. Meta-analysis: Early Age at Natural Menopause and Risk for All-Cause and Cardiovascular Mortality. Biomed Res Int 2021;15:6636856. DOI: 10.1155/2021/6636856

7. Бойцов С.А. и др. Артериальная гипертония среди лиц 25–64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная терапия и профилактика. 2014;13(4):4-14.

Fighters S.A. et al. Arterial hypertension among people aged 25-64 years: prevalence, awareness, treatment and control. Based on the materials of the ESSE research. Cardiovascular therapy and prevention. 2014;13(4):4-14 (in Russian).

8. Жернакова Ю.В., Железнова Е.А., Чазова И.Е. и др. Распространенность абдоминального ожирения в субъектах Российской Федерации и его связь с социально-экономическим статусом: результаты эпидемиологического исследования ЭССЭ-РФ. Терапевтический архив. 2018;(10):14-22.

Zhernakova Yu.V., Zheleznova E.A., Chazova I.E. et al. The prevalence of abdominal obesity in the subjects of the Russian Federation and its relationship with socio-economic status: the results of an epidemiological study of ESSE-RF. Therapeutic Archive. 2018;(10):14-22 (in Russian).

9. Подзолкова Н.М. и др. Современные возможности диагностики, лечения и профилактики возрастзависимых заболеваний у женщин. Менопаузальная гормональная терапия. М.: ГЭОТАР-Медиа, 2019.

Podzolkova N.M. et al. Modern possibilities of diagnosis, treatment and prevention of age-related diseases in women. Menopausal hormone therapy. Moscow: GEOTAR-Media, 2019 (in Russian).

10. Nanette K. Wenger et al. Call to Action for Cardiovascular Disease in Women: Epidemiology, Awareness, Access, and Delivery of Equitable Health Care: A Presidential Advisory From the American Heart Association. Circulation 2022;145:e1059–e1071. DOI: 10.1161/CIR. 0000000000001071

11. Boardman HMP et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev 2015;3:CD002229

12. Li YM, Lei X, Yu LL. Management of menopausal syndrome in women with dyslipidemia. Zhonghua Yu Fang Yi Xue Za Zhi 2023;57(11) :1908-14. DOI: 10.3760/cma.j.cn112150-20221216-01208

13. Anagnostis P, Bitzer J, Cano A et al. Menopause symptom management in women with dyslipidemias: An EMAS clinical guide. Maturitas 2020;135:82-8.

14. Hanggi W, Lippuner K, Riesen W et al. Long term influence of different postmenopausal hormone replacement regimens on serum lipids and lipoprotein(a): a randomised study. British Journal of Obstetrics and Gynaecology 1997;104:708-17. DOI: 10.1111/j.1471-0528.1997. tb11982.x

15. Van Ittersum FJ, Van Baal WM, Kenemans P et al. Ambulatory not office blood pressures decline during hormone replacement therapy in healthy postmenopausal women. American Journal of Hypertension1998;11:1147-52.

16. Менопауза и климактерическое состояние у женщины. Клинические рекомендации Минздрава России. М., 2021.

Menopause and menopausal condition in women. Clinical recommendations of the Ministry of Health of the Russian Federation. Moscow, 2021 (in Russian).

17. Yoshida Y, Chen Z, Baudier R et al. Early Menopause and Cardiovascular Disease Risk in Women With or Without Type 2 Diabetes: A Pooled Analysis of 9,374 Postmenopausal Women. Diabetes Care 2021;44:2564-72. DOI: 10.2337/dc21-1107

18. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause 2018;25(11):1362-87. DOI: 10.1097/ GME.0000000000001241

19. Slopiena R, Ewa Wender-Ozegowska E, Rogowicz-Frontczak A et al. Menopause and diabetes: EMAS clinical guide. Maturitas 2018;117:6–10. DOI: 10.1016/j.maturitas.2018.08.009

20. Godsland IF, Manassiev NA, Felton CA et al. Effects of low and high dose oestradiol and dydrogesterone therapy on insulin and lipoprotein metabolism in healthy postmenopausal women. Clin Endocrinol (Oxf) 2004;60:541-9. DOI: 10.1111/j.1365-2265.2004.02017.x

21. Rizzo MR, Leo S, De Franciscis P et al. Short-term effects of low-dose estrogen/drospirenone vs low-dose estrogen/dydrogesterone on glycemic fluctuations in postmenopausal women with metabolic syndrome. AGE 2014;36:265-74 DOI 10.1007/s11357-013-9554-7

22. Ambikairajah A, Walsh E, Tabatabaei-Jafari H, Cherbuin N. Fat mass changes during menopause: a meta-analysis. Am J Obstet Gynecol 2019;26:S0002-9378(19)30588-5

23. Peper JS, van den Heuvel MP, Mandl RC et al. Sex steroids and connectivity in the human brain: a review of neuroimaging studies. Psychoneuroendocrinology 2011;36:1101-13.

24. Vest RS, Pike CJ. Gender, sex steroid hormones, and Alzheimer’s disease. Horm Behav 2012;63:301-7.

25. Bojar I, Pinkas J, Gujski M et al. Postmenopausal cognitive changes and androgen levels in the context of apolipoprotein E polymorphism. Arch Med Sci 2017;13(5):1148-59. DOI: 10.5114/aoms.2016.62869

26. Vinogradova Y, Dening T, Hippisley-Cox J et al. Use of menopausal hormone therapy and risk of dementia: nested case-control studies using QResearch and CPRD databases. BMJ 2021;29;374:2182. DOI: 10.1136/bmj.n2182

27. Jayasena CN, Alkaabi FM, Liebers CS et al. A systematic review of randomized controlled trials investigating the efficacy and safety of testosterone therapy for female sexual dysfunction in postmenopausal women. Clin Endocrinol (Oxf) 2019;90:391-414.

28. , Dong-Fang Meng, ., et al. Obesity and risk of fracture in postmenopausal women: a meta-analysis of cohort studies. Ann Med 2023;55(1):2203515. DOI: 10.1080/07853890.2023.2203515

29. Zhang Z, X, L et al. The association between overweight/obesity and vertebral fractures in older adults: a meta-analysis of observational studies. Osteoporos Int 2021;32(6):1079-91. DOI: 10.1007/s00198-020-05764-8

30. Kyle UG, Genton L, Hans D et al. Age-related differences in fat-free mass, skeletal muscle, body cell mass and fat mass between 18 and 94 years. Eur J Clin Nutr 2001;55:663-72.

31. Hansen M. Female hormones: do they influence muscle and tendon protein metabolism? Proceedings of the Nutrition Society 2018;77:32-41. DOI: 10.1017/S0029665117001951

32. McGregor RA, Cameron-Smith D, Poppitt SD. It is not just muscle mass: a review of muscle quality, composition and metabolism during ageing as determinants of muscle function and mobility in later life. Longev Healthspan 2014;3(9).

33. Nanette K. Wenger et al. Call to Action for Cardiovascular Disease in Women: Epidemiology, Awareness, Access, and Delivery of Equitable Health Care: A Presidential Advisory From the American Heart Association. Circulation 2022;145:e1059-e1071. DOI: 10.1161/CIR. 0000000000001071

34. Witard OC, McGlory C, Hamilton DL et al. Growing older with health and vitality: a nexus of physical activity, exercise and nutrition. Biogerontology 2016;17:529-46.

35. Kraemer WJ & Ratamess NA. Hormonal responses and adaptations to resistance exercise and training. Sports Med 2005;35:339-61.

36. Smith GI, Yoshino J, Reeds DN et al. Testosterone and progesterone, but not estradiol, stimulate muscle protein synthesis in postmenopausal women. J Clin Endocrinol Meta 2014;99:256-65.

37. Miller BF, Hansen M, Olesen JL et al. Tendon collagen synthesis at rest and after exercise in women. J Appl Physiol 2006;102:541-6.

38. Hansen M, Kongsgaard M, Holm L et al. Effect of estrogen on tendon collagen synthesis, tendon structural characteristics, and biomechanical properties in postmenopausal women. J Appl Physiol 2009;106:1385-93.

39. Lee H, Petrofsky JS, Daher N et al. Differences in anterior cruciate ligament elasticity and force for knee flexion in women: oral contraceptive users versus non-oral contraceptive users. Eur J Appl Physiol 2014;114:285-94.

40. Hansen M, Boesen A, Holm L et al. Local administration of insulin-like growth factor-I (IGF-I) stimulates tendon collagen synthesis in humans. Scand J Med Sci Sports 2013;23:614-9.

41. Vestergaard PF, Hansen M, Frystyk J et al. Serum levels of bioactive IGF1 and physiological markers of ageing in healthy adults. Eur J Endocrinol 2014;170:229-36.

42. Chase JD, Phillips LJ, Brown M. Physical activity intervention effects on physical function among communitydwelling older adults: a systematic review and meta-analysis. J Aging PhysAct 2017;25:149-70.